195 related articles for article (PubMed ID: 29872523)
1. Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis.
Sakata N; Suenobu SI; Okano M; Ueda S; Kimura M; Takemura T
Rare Tumors; 2018; 10():2036361318776185. PubMed ID: 29872523
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary management of a neonate with kaposiform hemangioendothelioma with extensive cranial fossa destruction.
Khoei AA; Arias-Shah A; Kralik S; Mahajan P; Iacobas I; Fernandes CJ
SAGE Open Med Case Rep; 2022; 10():2050313X221142685. PubMed ID: 36545011
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
4. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
5. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
6. Progressive kaposiform hemangioendothelioma and sirolimus-related severe thrombocytopenia.
Ying H; Qiao C; Wang L; Lin X
Indian J Dermatol Venereol Leprol; 2023; 89(1):54-59. PubMed ID: 36688881
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
8. Treatment of childhood kaposiform hemangioendothelioma with sirolimus.
Blatt J; Stavas J; Moats-Staats B; Woosley J; Morrell DS
Pediatr Blood Cancer; 2010 Dec; 55(7):1396-8. PubMed ID: 20730884
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
10. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon.
Tribolet S; Hoyoux C; Boon LM; Cheruy C; Demarche M; Jamblin P; Roberti A; Willemaers V; Viellevoye R; Rigo V; Broux I
Arch Pediatr; 2019 Sep; 26(6):365-369. PubMed ID: 31353149
[TBL] [Abstract][Full Text] [Related]
11. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon in an infant girl.
Helligsø L; Mikkelsen TS; Hvas AM
Clin Case Rep; 2023 Sep; 11(9):e7859. PubMed ID: 37720715
[TBL] [Abstract][Full Text] [Related]
12. Case report: Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma.
Wang L; Li J; Wu C; Song D; Liu Z; Niu Y; Zhou J; Guo L
Front Pediatr; 2022; 10():949950. PubMed ID: 35990005
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate.
Cabrera TB; Speer AL; Greives MR; Goff DA; Menon NM; Reynolds EW
AJP Rep; 2020 Oct; 10(4):e390-e394. PubMed ID: 33214934
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
15. Neonatal kaposiform hemangioendothelioma of the spleen associated with Kasabach-Merritt phenomenon.
Shabtaie SA; Wang B; Owyong M; Ruiz-Mesa C; Corrales-Medina FF; Rojas CP; Infante JC; Neville HL; Perez EA; Sola JE; Hogan AR
J Pediatr Surg; 2016 Jun; 51(6):1047-50. PubMed ID: 27342010
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon.
Alaqeel AM; Alfurayh NA; Alhedyani AA; Alajlan SM
JAAD Case Rep; 2016 Nov; 2(6):457-461. PubMed ID: 27981218
[No Abstract] [Full Text] [Related]
17. Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges.
Zhou J; Li Y; Qiu T; Gong X; Yang K; Zhang X; Zhang Z; Lan Y; Hu F; Peng Q; Zhang Y; Kong F; Chen S; Ji Y
Int J Cancer; 2023 Aug; 153(3):600-608. PubMed ID: 36916140
[TBL] [Abstract][Full Text] [Related]
18. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Hermans DJ; van Beynum IM; van der Vijver RJ; Kool LJ; de Blaauw I; van der Vleuten CJ
J Pediatr Hematol Oncol; 2011 May; 33(4):e171-3. PubMed ID: 21516018
[TBL] [Abstract][Full Text] [Related]
19.
Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
[TBL] [Abstract][Full Text] [Related]
20. Mediastinal kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in a patient with no skin changes and a normal chest CT.
Wallenstein MB; Hole MK; McCarthy C; Fijalkowski N; Jeng M; Wong WB
Pediatr Hematol Oncol; 2014 Sep; 31(6):563-7. PubMed ID: 24047193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
